Programme

Thursday May 9

19.00-22.00	Welcome dinner at Comwell	

Friday May 10
Morning

9.00	Welcome	*President, Peter Ott (Aarhus)*

State of the art lectures
Chairs: Karl Heinz Weiss and Anil Dhawan

9.10	History of Wilson Disease	*James Dooley (London)*
9.30	Diagnosis of WD in 2019	*Aftab Ala (Guildford)*
9.50	Classical and atypical neuro-psychiatric presentations	*Tomasz Litwin (Warsaw)*
10.10	Specific challenges in pediatric Wilson patients	*Eve A. Roberts (Toronto)*
10.30	Coffee break	

Free papers
Chairs: Tomasz Litwin and Jan Pfeiffenberger

11.00	Major depressive disorder in patients with Wilson Disease and correlation with liver disease severity	*Michelle A. Camarata (Guildford)*
11.15	Intestinal knockout of ATP7B impairs copper homeostasis	*Sarah Guttmann (Münster)*
11.30	Wilson Disease: The French pediatric cohort	*Eduardo Couchonnal-Bedoya (Bron)*
11.45	Evolution of cognitive and psycho behavioral profile after a liver transplant in case of neurological aggravation	*Carla Machado (Paris)*
12.00	Cardiac tissue characterization in patients with Wilson Disease using cardiac magnetic resonance imaging	*Isabelle Mohr (Heidelberg)*
12.15	Lunch	

Wilson Aarhus
May 9-12 2019

Friday May 10
Afternoon

Genotype-phenotype part I. Genetic and non-genetic factors
Chairs: Roman S. Polishchuk and Roderick Houwen

13.15	ATP7B-/- mice as an animal model for Wilson Disease	*Svetlana Lutsenko (Baltimore)*
13.35	How to determine the functional consequences of a mutation using databases?	*Heinz Zoller (Innsbruck)*
13.55	Nongenetic factors modifying the phenotype	*Albert Friedrich Stättermayer (Vienna)*
14.15	Epigenetic factors in Wilson Disease	*Valentina Medici (Sacramento)*
14.35	Is WD a mitochondrial disorder?	*Hans Zischka (Munich)*
14.55	Coffee break and Poster session	

Genotype-phenotype part II. How frequent is WD?
Chairs: Radan Bruha and Oliver Bandmann

15.55	Genetic and clinical prevalence in UK	*Oliver Bandmann (Sheffield)*
16.10	Genetic and clinical prevalence in Sardinia	*Georgios Loudianos (Cagliari)*
16.25	Genetic and clinical prevalence in France	*Quentin Beaulieu (Paris)*
16.40	Analysis of the frequency and pathogenicity of ATP7B variants in a genomic dataset: Implications for Wilson Disease prevalence and penetrance	*Daniel Wallace (Brisbane)*

Chairs: Peter Ferenci and Lisbeth Birk Møller

16.55	Clinical profile and management of Wilson Disease among children and adolescents in an Indian Tertiary Care Centre	*Seema Alam (New Delhi)*
17.10	Genotype-phenotype correlation in India	*Harshad Devarbhavi (Bangalore)*
17.25	Does clinical and genetic data fit?	*Peter Ott (Aarhus)*
17.40	<u>Panel discussion</u> How frequent is WD. Is penetrance 100%?	
17.55	End of day	
19.00	Dinner at Ferdinand, Åboulevarden 28, 8000 Aarhus C	

Wilson Aarhus
May 9-12 2019

Saturday May 11
Morning

Studying the mutated protein
Chairs: Stephen G. Kaler and Sven C.D. van Ijzendoorn

9.00	Mutant interactome as a target for rescue of ATP7B function in Wilson Disease	*Roman S. Polishchuk (Pozzuoli)*
9.20	Structural studies by single-particle cryo-electron microscopy	*Poul Nissen (Aarhus)*
9.40	Copper binding to human P-type ATPase ATP7B	*Nina Salustros (Copenhagen)*
9.55	Searching for a new treatment of Wilson Disease	*Christine J. F. Nielsen (Aarhus)*
10.10	Differentiation of pluripotent stem cells to bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity	*Arend W. Overeem (Groningen)*
10.25	Coffee break	

Assessing copper metabolism
Chairs: Svetlana Lutsenko and Valentina Medici

11.00	Quantifying changes in the KF-Ring	*Jesper Hjortdal (Aarhus)*
11.15	In exchangeable copper we trust	*Nouzha Djebrani-Oussedik (Paris)*
11.30	Calculated free copper is better	*Frederick K. Askari (Ann Arbor)*
11.45	Evaluation of human Copper metabolism and the diagnosis of Wilson Disease by $^{64}CuCl_2$ positron emission tomography	*Thomas Damgaard Sandahl (Aarhus)*
12.00	Substantia nigra hyperechogenicity change over time in patients with Wilson Disease	*Marta Skowronska (Warsaw)*
12.15	CRISPR/CAS9-mediated correction of mutated copper transporter ATP7B	*Vanessa Sandfort (Münster)*
12.30	Lunch	

Saturday May 11
Afternoon

Workshop Session 1:
Recommendations for clinical trials in WD
Chairs: Aurélia Poujois and Peter Ott
Moderators: Eve A. Roberts and Peter Ferenci

13.30	Topic 1	Potential study designs in orphan disease	*Ralf-Dieter Hilgers (Aachen)*
13.50	Moderator	Comments and questions	*Peter Ferenci (Vienna)*
14.00	Panel discussion		
14.30	Topic 2	Study Endpoints – Liver	*Michael L. Schilsky (New Haven)*
14.50	Moderator	Comments and questions	*Eve A. Roberts (Toronto)*
15.00	Panel discussion		
15.30		Coffee break	

Workshop Session 2:
Chairs: Frederick K. Askari and Aftab Ala
Moderators: Michael L. Schilsky and Karl Heinz Weiss

16.00	Topic 3	Study Endpoints – Neurology and quantifying neurological changes	*Anna Czlonkowska (Warsaw)*
16.20	Moderator	Comments and questions	*Michael L. Schilsky (New Haven)*
16.30	Panel discussion		
17.00	Topic 4	Monitoring the patients	*Peter Ferenci (Vienna)*
17.20	Moderator	Comments and questions	*Karl Heinz Weiss (Heidelberg)*
17.30	Panel discussion		
18.00	End of day		
18.30		Dinner at NO16, Europaplads 16, 8000 Aarhus C	

Wilson Aarhus
May 9-12 2019

Sunday May 12
Morning

Treatment
Chairs: Eve A. Roberts and Piotr Socha

9.00	Treatment of Wilson Disease	*Peter Ferenci (Vienna)*
9.30	Liver transplantation in adults with WD	*Rodolphe Sobesky (Villejuif)*
9.45	Liver transplantation in children with WD	*Anil Dhawan (London)*
10.00	Controversy: Liver transplantation in neurologic disease	*Aurélia Poujois (Paris)*
10.15	Brain atrophy and neurological impairment in Wilson Disease	*Lukasz Smolinski (Warsaw)*
10.30	Coffee break	

Future treatments
Chairs: Anna Czlonkowska and Petr Dusek

11.00	Medical needs not addressed by current treatments	*Piotr Socha (Warsaw)*
11.15	Viral gene therapy for Menkes disease and related Copper Transport Disorders	*Stephen G. Kaler (Bethesda)*
11.30	Emerging therapies: hepatocyte transfer	*Sanjeev Gupta (Bronx)*
11.45	Evidence of Erad on ATP7B mutations indicates pharmacological chaperones as an optional individualized therapy for Wilson Disease	*Christina Hund (Rostock)*
12.00	Gene therapy	*Gloria González-Aseguinolaza (Pamplona)*
12.15	Closing remarks	*Peter Ott (Aarhus)*
12.25	Lunch	
13.30	Departure	